DEA Schedules Weird Benzos: Five Designer Drugs Hit Schedule I
Published Date: 3/2/2026
Rule
Summary
Starting April 1, 2026, the DEA is making it official: clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam are now permanently in Schedule I, meaning they’re considered dangerous with no accepted medical use. This affects anyone who makes, sells, or uses these drugs, bringing strict rules and penalties. The move also helps the U.S. follow international drug control agreements.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Five designer benzodiazepines now Schedule I
Starting April 1, 2026, clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam (and their salts/isomers) are permanently placed in Schedule I of the Controlled Substances Act. That means these substances are legally treated as having high abuse potential, no accepted medical use in the United States, and are subject to Schedule I controls.
Unauthorized possession and handling unlawful
Possession or handling of clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam in any manner not authorized by the CSA is unlawful as of April 1, 2026, and may subject the person to administrative, civil, and/or criminal sanctions. Retail sales to the general public of Schedule I substances are not allowed under the CSA.
Registration required to handle these drugs
Any person who handles (manufactures, distributes, imports/exports, engages in research, conducts instructional activities or chemical analysis with, or possesses) these five substances must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and comply with 21 CFR parts 1301 and 1312. Anyone currently handling these substances who is not registered must submit a registration application and may not continue to handle them unless DEA approves the application.
Research allowed but requires DEA permission
Placement in Schedule I does not preclude academic or scientific research, but anyone who wishes to conduct research on clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam must seek and obtain DEA permission and appropriate registration before handling them.
Schedule I regulatory controls apply (security, records)
As Schedule I substances, clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam must be handled under Schedule I security requirements, labeling and packaging rules, quotas for manufacture, biennial inventories, recordkeeping and reporting, DEA order-form requirements, and import/export controls per the CSA and implementing CFR parts (e.g., 21 CFR parts 1301, 1302, 1303, 1304, 1312, and 1317).
Surrender or transfer of existing stocks before effective date
Any person unwilling or unable to obtain a Schedule I registration must surrender or transfer all quantities of these five substances to a DEA-registered person before the effective date of the final scheduling action, and any disposal must follow 21 CFR part 1317 and applicable laws. The effective date for the permanent scheduling is April 1, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-14286, Importer of Controlled Substances Application: Catalent Greenville, Inc.
Catalent Greenville, Inc. wants to become an official importer of some powerful controlled substances, including LSD and related drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
2026-14136, Barlow St-Clair Lynch, M.D.; Decision and Order
Dr. Barlow St-Clair Lynch from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
2026-14135, David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-14137, Shane Lydon, M.D.; Decision and Order
Dr. Shane Lydon's license to handle controlled substances in Maine has been revoked because he lost his state authority and didn’t ask for a hearing. This means he can no longer prescribe or manage these drugs, effective immediately. Anyone relying on his registration should update their records and note this change to avoid legal trouble.
Previous / Next Documents
Previous: 2026-04093, Publication of Venezuela Sanctions Regulations Web General License 5T
The Treasury Department just made it official: starting February 3, 2026, certain deals involving Venezuela’s 2020 8.5% bond are allowed again, replacing the old rules from June 2025. This update affects anyone handling these bonds, letting them trade or finance them without breaking sanctions. It’s a big move that could open up new money flows and opportunities tied to Venezuela’s debt.
Next: 2026-04115, Cotton Board Rules and Regulations: Adjusting Supplemental Assessment on Imports (2025 Amendments)
The USDA planned to lower the fees on imported cotton to match those on U.S. cotton, but after getting a big negative comment, they decided to cancel that change. This means importers won’t see any new fee adjustments for now, keeping things steady until further notice. The withdrawal took effect on February 26, 2026, so everyone involved should stay tuned for updates.